SI3334431T1 - 5-bromo-2,6-di-(1h-pirazol-l-il)pyrimidin-4-amin za uporabo v zdravljenju raka - Google Patents
5-bromo-2,6-di-(1h-pirazol-l-il)pyrimidin-4-amin za uporabo v zdravljenju rakaInfo
- Publication number
- SI3334431T1 SI3334431T1 SI201630543T SI201630543T SI3334431T1 SI 3334431 T1 SI3334431 T1 SI 3334431T1 SI 201630543 T SI201630543 T SI 201630543T SI 201630543 T SI201630543 T SI 201630543T SI 3334431 T1 SI3334431 T1 SI 3334431T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pyrazol
- pyrimidin
- bromo
- cancer
- amine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15382425 | 2015-08-11 | ||
US201662335984P | 2016-05-13 | 2016-05-13 | |
EP16766384.8A EP3334431B9 (en) | 2015-08-11 | 2016-08-10 | 5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer |
PCT/IB2016/054834 WO2017025918A1 (en) | 2015-08-11 | 2016-08-10 | 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3334431T1 true SI3334431T1 (sl) | 2020-01-31 |
Family
ID=53887054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201630543T SI3334431T1 (sl) | 2015-08-11 | 2016-08-10 | 5-bromo-2,6-di-(1h-pirazol-l-il)pyrimidin-4-amin za uporabo v zdravljenju raka |
Country Status (17)
Country | Link |
---|---|
US (1) | US10561653B2 (sl) |
EP (1) | EP3334431B9 (sl) |
JP (1) | JP6663493B2 (sl) |
KR (1) | KR102114562B1 (sl) |
CN (2) | CN114129568A (sl) |
AU (1) | AU2016306090B2 (sl) |
BR (1) | BR112018002585A2 (sl) |
CA (1) | CA2994918C (sl) |
CY (1) | CY1122966T1 (sl) |
MX (1) | MX2018001721A (sl) |
PH (1) | PH12018500284A1 (sl) |
PL (1) | PL3334431T3 (sl) |
RS (1) | RS59688B1 (sl) |
SA (1) | SA518390901B1 (sl) |
SG (1) | SG10202111808WA (sl) |
SI (1) | SI3334431T1 (sl) |
WO (1) | WO2017025918A1 (sl) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
EP3659621A1 (en) | 2014-09-13 | 2020-06-03 | Novartis AG | Combination therapies for cancer |
EP3374381A4 (en) | 2015-11-09 | 2019-05-15 | The University Of British Columbia | EPITAOPES IN THE CENTRAL REGION OF BETA-AMYLOID AND RELATED CONFORMATIONAL ANTIBODIES |
US11229703B2 (en) | 2016-04-06 | 2022-01-25 | Noxopharm Limited | Radiotherapy improvements |
EP4005567A1 (en) | 2016-04-06 | 2022-06-01 | Noxopharm Limited | Isoflavonoid composition with improved pharmacokinetics |
AU2018218557B9 (en) | 2017-02-08 | 2021-06-24 | Novartis Ag | FGF21 mimetic antibodies and uses thereof |
AU2018217963B2 (en) * | 2017-02-10 | 2020-11-19 | Novartis Ag | 1-(4-amino-5-bromo-6-(1 H-pyrazol-1-yl)pyrimidin-2-yl)-1 H-pyrazol-4-ol and use thereof in the treatment of cancer |
JOP20190279A1 (ar) * | 2017-05-31 | 2019-11-28 | Novartis Ag | الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
EP3641812A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
EP3574020A4 (en) * | 2017-07-18 | 2020-03-25 | The University of British Columbia | ANTIBODIES AGAINST AMYLOID BETA |
CA3070273A1 (en) | 2017-07-18 | 2019-01-24 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
AU2018302178A1 (en) | 2017-07-18 | 2020-02-13 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
CN111655288A (zh) | 2017-11-16 | 2020-09-11 | 诺华股份有限公司 | 组合疗法 |
CA3083949A1 (en) | 2017-11-30 | 2020-06-06 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
EP3755333A4 (en) | 2018-02-16 | 2021-11-17 | Arcus Biosciences, Inc. | DOSING WITH AN AZOLOPYRIMIDINE COMPOUND |
WO2019178269A2 (en) | 2018-03-14 | 2019-09-19 | Surface Oncology, Inc. | Antibodies that bind cd39 and uses thereof |
KR102183677B1 (ko) | 2018-04-26 | 2020-11-27 | 주식회사 엘지화학 | 광학 디바이스 및 이의 용도 |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
EP3802611A2 (en) | 2018-06-01 | 2021-04-14 | Novartis AG | Binding molecules against bcma and uses thereof |
BR112020024700A2 (pt) | 2018-06-04 | 2021-03-02 | Exscientia Ltd | compostos de pirazolopirimidina como antagonistas receptores de adenosina |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
MX2021007392A (es) | 2018-12-20 | 2021-08-24 | Novartis Ag | Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
JP2022523473A (ja) | 2019-01-18 | 2022-04-25 | ニューベイション・バイオ・インコーポレイテッド | 1,8-ナフチリジジノン化合物およびそれらの使用 |
CA3126702A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
MX2021009763A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. |
AU2020351122A1 (en) | 2019-09-16 | 2022-02-17 | Surface Oncology, Inc. | Anti-CD39 antibody compositions and methods |
TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與entpd2抗體之組合療法 |
US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
BR112022004302A2 (pt) | 2019-09-25 | 2022-06-21 | Surface Oncology Inc | Anticorpos anti-il-27 e usos dos mesmos |
AU2020406350A1 (en) | 2019-12-20 | 2022-08-11 | Novartis Ag | Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
JP2023519990A (ja) | 2020-03-30 | 2023-05-15 | ノクソファーム リミティド | 感染に関連する炎症の治療のための方法 |
KR20210152312A (ko) * | 2020-06-08 | 2021-12-15 | 주식회사 종근당 | 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물 |
JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | 3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン |
CN116134027A (zh) | 2020-08-03 | 2023-05-16 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
WO2022162569A1 (en) | 2021-01-29 | 2022-08-04 | Novartis Ag | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6339875A (ja) | 1986-08-05 | 1988-02-20 | Nissin Food Prod Co Ltd | ピリミジン誘導体 |
US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
CA2589418A1 (en) * | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
WO2003050241A2 (en) | 2001-12-12 | 2003-06-19 | The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services | Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation |
JP2007514003A (ja) | 2003-12-15 | 2007-05-31 | アルミラル プロデスファルマ アーゲー | アデノシン受容体アンタゴニストとしての2,6−ビスヘテロアリール−4−アミノピリミジン |
ATE502936T1 (de) | 2005-04-11 | 2011-04-15 | Almirall Sa | 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten |
WO2008147482A2 (en) * | 2007-02-13 | 2008-12-04 | Northeastern University | Methods and compositions for improving immune responses |
EP2132197A2 (en) | 2007-03-21 | 2009-12-16 | Almirall, S.A. | Substituted pyrimidines as adenosine receptor antagonists |
WO2009033161A1 (en) | 2007-09-07 | 2009-03-12 | The John Hopkins University | Adenosine receptor agonists and antagonists to modulate t cell responses |
DK2350129T3 (en) | 2008-08-25 | 2015-08-31 | Amplimmune Inc | PREPARATIONS WITH PD-1 ANTAGONISTS AND PROCEDURES FOR USE THEREOF |
EP3530672B1 (en) * | 2008-09-26 | 2024-05-01 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
ES2365960B1 (es) * | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
RU2016122957A (ru) | 2013-11-11 | 2017-12-19 | Армо Байосайенсиз, Инк. | Способы применения интерлейкина-10 для лечения заболеваний и расстройств |
JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
WO2017019896A1 (en) * | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
-
2016
- 2016-08-10 JP JP2018527029A patent/JP6663493B2/ja active Active
- 2016-08-10 WO PCT/IB2016/054834 patent/WO2017025918A1/en active Application Filing
- 2016-08-10 CN CN202111365426.3A patent/CN114129568A/zh active Pending
- 2016-08-10 AU AU2016306090A patent/AU2016306090B2/en active Active
- 2016-08-10 CA CA2994918A patent/CA2994918C/en active Active
- 2016-08-10 MX MX2018001721A patent/MX2018001721A/es active IP Right Grant
- 2016-08-10 PL PL16766384T patent/PL3334431T3/pl unknown
- 2016-08-10 CN CN201680059231.7A patent/CN108348521B/zh active Active
- 2016-08-10 EP EP16766384.8A patent/EP3334431B9/en active Active
- 2016-08-10 RS RS20191573A patent/RS59688B1/sr unknown
- 2016-08-10 US US15/751,140 patent/US10561653B2/en active Active
- 2016-08-10 SG SG10202111808WA patent/SG10202111808WA/en unknown
- 2016-08-10 BR BR112018002585-2A patent/BR112018002585A2/pt not_active Application Discontinuation
- 2016-08-10 SI SI201630543T patent/SI3334431T1/sl unknown
- 2016-08-10 KR KR1020187006576A patent/KR102114562B1/ko active IP Right Grant
-
2018
- 2018-02-08 PH PH12018500284A patent/PH12018500284A1/en unknown
- 2018-02-11 SA SA518390901A patent/SA518390901B1/ar unknown
-
2019
- 2019-12-19 CY CY20191101337T patent/CY1122966T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PH12018500284A1 (en) | 2018-08-13 |
RS59688B1 (sr) | 2020-01-31 |
JP2018528264A (ja) | 2018-09-27 |
EP3334431B9 (en) | 2020-03-04 |
CY1122966T1 (el) | 2021-10-29 |
MX2018001721A (es) | 2018-09-06 |
US10561653B2 (en) | 2020-02-18 |
AU2016306090B2 (en) | 2019-05-02 |
EP3334431B1 (en) | 2019-09-25 |
SG10202111808WA (en) | 2021-11-29 |
BR112018002585A2 (pt) | 2018-10-16 |
CN114129568A (zh) | 2022-03-04 |
US20180228802A1 (en) | 2018-08-16 |
PL3334431T3 (pl) | 2020-03-31 |
CN108348521A (zh) | 2018-07-31 |
CA2994918A1 (en) | 2017-02-16 |
JP6663493B2 (ja) | 2020-03-11 |
AU2016306090A1 (en) | 2018-03-08 |
KR20180048684A (ko) | 2018-05-10 |
SA518390901B1 (ar) | 2023-01-19 |
CN108348521B (zh) | 2021-12-03 |
KR102114562B1 (ko) | 2020-05-26 |
EP3334431A1 (en) | 2018-06-20 |
WO2017025918A1 (en) | 2017-02-16 |
CA2994918C (en) | 2024-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL3334431T3 (pl) | 5-bromo-2,6-di-(1H-pirazol-1-ilo)pirymidyno-4-amina do zastosowania w leczeniu nowotworu złośliwego | |
ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
HK1256283A1 (zh) | 治療癌症有用的二氫咪唑並吡嗪酮衍生物 | |
IL251905B (en) | Epilimod for use in the treatment of kidney cancer | |
IL276733A (en) | Use of Aribolin in cancer treatment | |
IL251903A0 (en) | Epilimod for use in the treatment of colon cancer | |
IL262143A (en) | Improvements in cancer treatment | |
EP3337784A4 (en) | USE OF UREIDOMUSTIN (BO-1055) IN THE TREATMENT OF CANCER | |
PL3258931T3 (pl) | Zastosowanie kabazitakselu w leczeniu nowotworu złośliwego prostaty | |
IL253933A0 (en) | History of pyrimidine use in the treatment of cancer | |
IL269121A (en) | Usl-311 for use in the treatment of cancer | |
HK1249409B (zh) | 用於治療癌症的5-溴-2,6-二-(1h-吡唑-1-基)嘧啶-4-胺 | |
GB201522433D0 (en) | Cancer treatment | |
GB2578008B (en) | 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment | |
PT3580211T (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro | |
GB2553684B (en) | Ethynylxanthines, preparation and use for cancer treatment |